利莫那班致精神分裂症患者紧张症：病例报告

Rimonabant-induced catatonia in schizophrenia: A case report.

机构信息

The Metabolic Clinic in Psychiatry, Department of Psychiatry, National Institute of Mental Health & Neurosciences, Hosur Road, Bangalore 560029, Karnataka, India.

出版信息

Obes Res Clin Pract. 2009 Nov;3(4):237-9. doi: 10.1016/j.orcp.2009.04.002.

DOI:10.1016/j.orcp.2009.04.002

PMID:24973151

Abstract

Patients with psychiatric illness have higher rates of mortality and medical co-morbidity related to increased rates of diabetes mellitus and cardiovascular disease. Rimonabant, a cannabinoid receptor (CB1) antagonist, is an anti-obesity agent and decreases risk for metabolic syndrome. Though there are reports of rimonabant associated with adverse psychiatric events like depression, rimonabant-induced catatonia is not reported. In this first time report, we describe a patient with schizophrenia developing catatonia possibly due to rimonabant.:

摘要

精神疾病患者的死亡率和与糖尿病和心血管疾病发病率增加相关的合并症发生率更高。安非他酮，一种大麻素受体 (CB1) 拮抗剂，是一种抗肥胖药物，可降低代谢综合征的风险。尽管有报道称安非他酮与抑郁等不良精神事件有关，但尚未报道安非他酮引起的紧张症。在首次报告中，我们描述了一名患有精神分裂症的患者可能因安非他酮而出现紧张症。